LTFS
KPTI icon

Ladenburg Thalmann Financial Services’s Karyopharm Therapeutics KPTI Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$804K Buy
2,794
+8
+0.3% +$1.74K 0.01% 1436
2019
Q3 		$402K Hold
2,786
– – ﹤0.01% 1932
2019
Q2 		$250K Hold
2,786
– – ﹤0.01% 2306
2019
Q1 		$244K Hold
2,786
– – ﹤0.01% 2248
2018
Q4 		$392K Buy
+2,786
New +$470K ﹤0.01% 1720

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ladenburg Thalmann Financial Services's KPTI Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Karyopharm Therapeutics (KPTI) stake by 0.29% in Q4 2019, buying an estimated $1.74K and bringing the position to 2,794 shares worth $804K. The position accounts for 0.01% of the portfolio, ranked #1436.

Ladenburg Thalmann Financial Services first reported a position in KPTI in Q4 2018 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold KPTI as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 2,794 shares of Karyopharm Therapeutics worth $804K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 8 Karyopharm Therapeutics shares in Q4 2019, an estimated $1.74K.
  • Karyopharm Therapeutics made up 0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1436 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Karyopharm Therapeutics in Q4 2018 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.